OPTN News and Press, OptiNose Inc. From 03/07/22

The commercial-stage pharmaceutical company, Optinose (NASDAQ:OPTN) announced on Monday that its Phase 3 trial for Xhance (fluticasone propionate) met both primary endpoints with statistical significance in patients with chronic sinusitis. Comparing those who received an Exhalation Delivery S...

The commercial-stage pharmaceutical company, Optinose (NASDAQ:OPTN) announced on Monday that its Phase 3 trial for Xhance (fluticasone propionate) met both primary endpoints with statistical significance in patients with chronic sinusitis. Compared to the those who received an Exhalation Deli...

XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug treatments for the 30 million adults in the U.S. with chronic sinusitis ...

Conference Call and Webcast to be held March 8, 2021 at 8:00 a.m. Eastern Time Company to Present at the Cowen 42 nd Annual Health Care Conference on March 9, 2022 YARDLEY, Pa., March 04, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical com...

YARDLEY, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Drs. Eric Bednarski and Kyle Dempsey as new directors. ...

YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business upda...

YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the closing of the previously announced underwritten public offering of 28,750,000 shares of it...

Gainers: InMed Pharmaceuticals (NASDAQ:INM) +47%, EyePoint Pharmaceuticals (NASDAQ:EYPT) +24%, Varex Imaging (NASDAQ:VREX) +12%, OptiNose (NASDAQ:OPTN) +10%, Talkspace (NASDAQ:TALK) +7%. Losers: Cassava Sciences (NASDAQ:SAVA) -26%, Eloxx Pharm...

OptiNose, Inc. (OPTN) Q3 2021 Earnings Conference Call November 16, 2021 08:30 AM ET Company Participants Jonathan Neely - VP, IR & Business Operations Peter Miller - CEO & Director Keith Goldan - CFO Ramy Mahmoud - President & COO Conference Call Participants Gary Nachman - BMO C...

Gainers: BIMI International Medical (NASDAQ:BIMI) +55%. Kezar Life Sciences (NASDAQ:KZR) +31%. CNS Pharmaceuticals (NASDAQ:CNSP) +28%. ReTo Eco-Solutions (NASDAQ:RETO) +28%. Progenity (NASDAQ:PROG) +27%. PLBY Group (NASDAQ:PLBY) +27%. IonQ (NYSE:IONQ) +25%. Kuke (NYSE:KUKE) +21%. On Holding (...